Research Article

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

Table 2

Change from baseline at week 12 in mean daily number of urgency episodes.

Dry populationWet population§
Placebo (N = 115)Vibegron (N = 123)Tolterodine (N = 98)Placebo (N = 405)Vibegron (N = 403)Tolterodine (N = 319)

Change from baseline at week 12
n10310992372383286
LS mean (SE)‒1.6 (0.34)‒2.6 (0.33)‒2.0 (0.36)‒2.4 (0.17)‒3.0 (0.17)‒2.8 (0.19)
95% CI‒2.2 to ‒0.9‒3.2 to ‒2.0‒2.7 to ‒1.3‒2.7 to ‒2.0‒3.3 to ‒2.6‒3.2 to ‒2.4
Active ‒ placebo
LSMD (SE)‒1.0 (0.47)‒0.4 (0.49)‒0.6 (0.24)‒0.4 (0.26)
95% CI‒2.0 to ‒0.1‒1.4 to 0.5‒1.0 to ‒0.1‒1.0 to 0.1

LS, least squares; LSMD, LS mean difference. Analyzed using a mixed model for repeated measures with covariates for study visit, baseline number of urgency episodes, and treatment by study visit interaction. All randomized patients with OAB dry at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. §All randomized patients with OAB wet at study entry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline urge urinary incontinence measurement.